Développement d'un outil de gestion graduée des risques spécifique au cas des nanomatériaux : rapport d'appui scientifique et technique

L' évaluation quantitative des dangers et des expositions aux nanomatériaux se heurte à de nombreuses incertitudes qui ne seront levées qu'à mesure de la progression des connaissances scientifiques de leurs propriétés. L' une des conséquences de ces incertitudes est que les valeurs limites d'exposition professionnelle définies actuellement pour les poussières ne sont pas nécessairement pertinentes aux nanomatériaux. En l'absence de référentiel quantitatif et, à la demande de la DGS pour éclairer les réflexions de l' AFNOR et de l'ISO sur le sujet, une démarche de gestion graduée des risques (control banding) a été élaborée au sein de l' Anses. Ce développement a été réalisé à l'aide d'un groupe d'experts rapporteurs rattaché au Comité d'experts spécialisés évaluation des risques liés aux agents physiques, aux nouvelles technologies et aux grands aménagements. La mise en oeuvre de la démarche de gestion graduée des risques proposée repose sur quatre grandes étapes: 1. Le recueil des informations. Cette étape consiste à réunir les informations disponibles sur les dangers du nanomatériau manufacturé considéré ; ainsi que sur l'exposition potentielle des personnes aux postes de travail (observation sur le terrain, mesures, etc.). 2. L'attribution d'une bande de danger. Le danger potentiel du nanomatériau manufacturé présent, qu'il soit brut où incorporé dans une matrice (liquide ou solide) est évalué dans cette étape. La bande danger attribuée tient compte de la dangerosité du produit bulk ou de sa substance analogue à l'échelle non-nanométrique, de la bio-persistance du matériau (pour les matériaux fibreux), de sa solubilité et de son éventuelle réactivité. 3. Attribution d'une bande d'exposition. La bande d'exposition du nanomatériau manufacturé considéré ou du produit en contenant est définie par le niveau de potentiel d'émission du produit. Elle tient compte de sa forme physique (solide, liquide, poudre aérosol), de sa pulvérulence et de sa volatilité. Le nombre de travailleurs, la fréquence, la durée d'exposition ainsi que la quantité mise en oeuvre ne sont pas pris en compte, contrairement à une évaluation classique des risques chimiques. 4. Obtention d'une bande de maîtrise des risques. Le croisement des bandes de dangers et d'exposition préalablement attribuées permet de défi nir le niveau de maîtrise du risque. Il fait correspondre les moyens techniques et organisationnels à mettre en oeuvre pour maintenir le risque au niveau le plus faible possible. Un plan d'action est ensuite défi ni pour garantir l'effi cacité de la prévention recommandée par le niveau de maîtrise déterminé. Il tient compte des mesures de prévention déjà existantes et les renforce si nécessaire. Si les mesures indiquées par le niveau de maîtrise de risque ne sont pas réalisables, par exemple, pour des raisons techniques ou budgétaires, une évaluation de risque approfondie devra être réalisée par un expert. La gestion graduée des risques est une méthode alternative pour réaliser une évaluation qualitative de risques et mettre en place des moyens de prévention sans recourir à une évaluation quantitative des risques. Son utilisation semble particulièrement adaptée au contexte des nanomatériaux manufacturés, pour lequel les choix de valeurs de référence (Valeurs limites d'exposition en milieu professionnel) et des techniques de mesurage appropriées souffrent d'une grande incertitude. La démarche proposée repose sur des critères simples, accessibles dans la littérature scientifi que ou via les données techniques relatives aux produits utilisés. Pour autant, sa mise en oeuvre requiert des compétences minimales dans les domaines de la prévention des risques chimiques (chimie, toxicologie, etc.), des nanosciences et des nanotechnologies.

Inflammation And Autoimmune Responses Are Independent Of Peripheral Mhc Class Ii Expression Driven By Ciita Piv In Collagen Induced Arthritis

Background In rheumatoid arthritis (RA), non-professional antigen presenting cells (APCs) such as fi broblast-like synoviocytes (FLS) can express MHC class II (MHCII) molecules and function as non-professional APCs in vitro.Objective To examine the regulation of MHCII expression in FLS and to investigate the role of FLS as non-professional APCs in collagen-induced arthritis (CIA). Methods Expression of MHCII, CIITA and Ciita isoforms pI, pIII and pIV was examined by RT-qPCR, immunohistochemistry and fl ow cytometry in human synovial tissues, arthritic mouse joints and human as well as mouse FLS. CIA was induced in mice knockout for the isoform IV of Ciita (pIV-/-), in pIV-/- mice transgenic for CIITA in the thymus (pIV-/- K14 CIITA) and in control littermates in the DBA/1 background by immunising with bovine collagen type II (CII) in complete Freund's adjuvant.Results HLA-DRA, total CIITA and CIITA pIII mRNA levels were signifi cantly increased in the synovial tissues from RA compared to osteoarthritis patients. Human FLS expressed surface MHCII via CIITA pIII and pIV, while MHCII expression in murine FLS was entirely mediated by pIV. pIV-/- mice lacked both inducible MHCII expression on non-professional APCs including FLS, and in the thymic cortex. The thymic defect in pIV-/- mice impaired CD4+ positive selection, thus protecting pIV-/- mice from CIA by preventing CD4+ T cells immune responses against CII and blocking the release of IFN-γ and IL-17 in ex vivo stimulated lymph node cells. The production of T dependent, arthritogenic anti-CII antibodies was also impaired in pIV-/- mice. A normal thymic expression of MHCII and CD4+ T cell repertoire was obtained in pIV-/- K14 CIITA Tg mice. Immune responses against CII were restored in pIV-/- K14 CIITA Tg mice, as well as the arthritis incidence and clinical severity despite the lack of MHCII expression by mouse FLS. At histology, infl ammation andneutrophils infi ltration scores were not reduced in pIV-/- K14 CIITA Tg mice, while the bone erosion score was signifi cantly lower than in controls.Conclusion Over expression of MHCII is tightly correlated with CIITA pIII in the arthritic human synovium. MHCII is induced via CIITA pIII and pIV in human FLS. In the mouse, MHCII expression in the thymic cortex and in FLS is strictly dependent upon Ciita pIV. The lack of Ciita pIV in the periphery of pIV-/- K14 CIITA Tg mice lowered the bone erosion score but did not signifi cantly protect from infl ammation and autoimmune responses in CIA.

Peter Jarvis - monitieteisyyden ja tieteiden välisen yhteistyön apostoli

Professori Peter Jarvisin haastattelu. Haastattelijoina Anneli Kajanto ja Kari Kantasalmi

Eficiência simbiótica de isolados de rizóbio noduladores de feijão-fava (Phaseolus lunatus L.)

Em leguminosas tropicais, a cuidadosa seleção de estirpes de rizóbio, entre outros fatores, é fundamental para a eficiência da fixação biológica de N2 (FBN). Essa seleção deve ser feita para as leguminosas de interesse social e econômico, entre elas o feijão-fava (Phaseolus lunatus L.). O objetivo deste trabalho foi avaliar a eficiência simbiótica de rizóbios nativos de duas regiões do Piauí produtoras de feijão-fava. Foram avaliados 17 isolados e duas estirpes de referência (CIAT 899 e NGR 234), em casa de vegetação, utilizando-se vasos de Leonard autoclavados, no delineamento experimental inteiramente ao acaso, com três repetições. O genótipo de feijão-fava utilizado foi o UFPI-468. A inoculação foi feita por ocasião do plantio. A coleta foi realizada aos 34 dias após o plantio, sendo avaliadas as seguintes características: matéria seca da parte aérea (MSPA), da raiz (MSR) e dos nódulos (MSN); relação MSPA/MSR; N acumulado (Nac) na MSPA e a eficiência da fixação de N2. Foi observada diferença significativa entre os isolados em todas as características, exceto em MSR. Em geral, os isolados ISO-18, ISO-23, ISO-24, ISO-25, ISO-30, ISO-32, ISO-35, ISO-36, ISO-43 e ISO-45 apresentaram os melhores índices de MSPA, MSR, MSPA/MSR, Nac e eficiência da fixação de N2, em relação aos isolados ISO-2, ISO-9, ISO-16, ISO-40 e testemunha absoluta. As características avaliadas foram suficientes para discriminar e selecionar isolados eficientes na nodulação em feijão-fava, contribuindo para a efetividade da FBN. Os melhores isolados apresentaram bom desempenho no fornecimento de N às plantas, podendo ser recomendados para testes de eficiência agronômica.

Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after (90) Y-ibritumomab-tiuxetan.

Radioimmunotherapies with Zevalin® (RIT-Z) showed encouraging results in patients with relapsed/refractory follicular lymphoma (FL), leading frequently to failure-free intervals longer than those achieved by the last previous therapy. We compared time-to-event variables obtained before and after RIT-Z in patients with relapsed FL, previously exposed to rituximab. All patients with relapsed non-transformed, non-refractory, non-rituximab-naïve FL who have been treated with RIT-Z in two different centres in Europe were included. Staging and response were assessed by contrast-enhanced CT in all patients; PET/CT was performed according to local availability. Event-free survival (EFS) and time to next treatment (TTNT) following the last previous therapy and after RIT-Z were compared. Pre-therapy characteristics were tested in univariate analyses for prediction of outcomes. A description of the patterns of relapse was also provided. Among 70 patients treated, only 16 fulfilled the inclusion criteria. They were treated with a median of 3 prior lines of chemo-immunotherapies, including a median of 2 rituximab-containing regimens; 6 patients had undergone myeloablative chemotherapy with autologous stem cell rescue (ASCT). Overall response rates were 10 (62%) CR/CRu, 3 (19%) PR and 3 (19%) PD; response rates were similar in patients with prior ASCT. After RIT-Z only few patients obtained EFS and TTNT longer than after the last previous therapy. All four patients receiving rituximab maintenance were without progression 12 months after RIT-Z. Relapses occurred in both previously and newly involved sites; a significant association was found between the number of pathologic sites involved prior to RIT-Z and subsequent TTNT. Despite the excellent response rate, the duration of response was shorter than the previous one confirming the known trend of relapses to occur earlier after subsequent treatments. Rituximab maintenance after RIT-Z showed encouraging results in terms of prolonging EFS, warranting further studies. Copyright © 2010 John Wiley & Sons, Ltd.

Equivalence Between the Lagrangian and Hamiltonian Formalisms for Constrained Systems

The equivalence between the Lagrangian and Hamiltonian formalism is studied for constraint systems. A procedure to construct the Lagrangian constraints from the Hamiltonian constraints is given. Those Hamiltonian constraints that are first class with respect to the Hamiltonian constraints produce Lagrangian constraints that are FL-projectable.

Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence.

Non-Hodgkin's lymphoma (NHL) comprises both indolent forms, including follicular lymphoma (FL) and marginal zone lymphoma (MZL), and aggressive forms, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). FL and DLBCL are the most common subtypes of indolent and aggressive NHL, respectively. Although these lymphomas exhibit different clinical behaviors and outcomes, the prognosis is negatively affected in both DLBCL and FL by the lack of a complete response (CR) with standard treatment options. The aim of therapy should therefore be achievement of a CR, which is not only associated with longer progression-free survival (PFS) and overall survival times, but is also a prerequisite for a cure, particularly in DLBCL. Consolidation treatment with radioimmunotherapy (RIT) is an innovative treatment approach to increase CR rates. Phase II studies have indicated promising results with yttrium-90 ((90)Y)-ibritumomab tiuxetan and iodine-131 ((131)I)-tositumomab as consolidation following induction therapy for previously untreated patients with advanced FL. More recently, investigators reported a marked increase in CR rates and significant improvements in PFS using standard chemotherapy regimens followed by (90)Y-ibritumomab tiuxetan in a phase III randomized trial in patients with previously untreated FL. Data also suggest that RIT may play a role in the treatment of high-risk DLBCL, with encouraging PFS results from a phase II trial of (90)Y-ibritumomab tiuxetan consolidation following induction with rituximab plus chemotherapy in elderly patients with previously untreated DLBCL. With the higher CR rates and longer PFS times observed in patients with FL and DLBCL, as well as encouraging early data from MZL and MCL consolidation trials, RIT appears to have an important role in the treatment of patients with NHL.

90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial.

PURPOSE Updated results are presented after a median follow-up of 7.3 years from the phase III First-Line Indolent Trial of yttrium-90 ((90)Y) -ibritumomab tiuxetan in advanced-stage follicular lymphoma (FL) in first remission. PATIENTS AND METHODS Patients with CD20(+) stage III or IV FL with complete response (CR), unconfirmed CR (CRu), or partial response (PR) after first-line induction treatment were randomly assigned to (90)Y-ibritumomab consolidation therapy (rituximab 250 mg/m(2) days -7 and 0, then (90)Y-ibritumomab 14.8 MBq/kg day 0; maximum 1,184 MBq) or no further treatment (control). Primary end point was progression-free survival (PFS) from date of random assignment. Results For 409 patients available for analysis ((90)Y-ibritumomab, n = 207; control, n = 202), estimated 8-year overall PFS was 41% with (90)Y-ibritumomab versus 22% for control (hazard ratio [HR], 0.47; P < .001). For patients in CR/CRu after induction, 8-year PFS with (90)Y-ibritumomab was 48% versus 32% for control (HR, 0.61; P = .008), and for PR patients, it was 33% versus 10% (HR, 0.38; P < .001). For (90)Y-ibritumomab consolidation, median PFS was 4.1 years (v 1.1 years for control; P < .001). Median time to next treatment (TTNT) was 8.1 years for (90)Y-ibritumomab versus 3.0 years for control (P < .001) with approximately 80% response rates to second-line therapy in either arm, including autologous stem-cell transplantation. No unexpected toxicities emerged during long-term follow-up. Estimated between-group 8-year overall survival rates were similar. Annualized incidence rate of myelodysplastic syndrome/acute myeloblastic leukemia was 0.50% versus 0.07% in (90)Y-ibritumomab and control groups, respectively (P = .042). CONCLUSION (90)Y-ibritumomab consolidation after achieving PR or CR/CRu to induction confers 3-year benefit in median PFS with durable 19% PFS advantage at 8 years and improves TTNT by 5.1 years for patients with advanced FL.